MDK and cancer: The pooled sensitivity and specificity of serum MK were 0.78 (95% CI = 0.68–0.85) and 0.83 (95% CI = 0.72–0.90) respectively, indicating that 78% of cancer patients had high serum MK levels and that 83% of the non-cancer patients had low serum MK levels.